<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004108</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067329</org_study_id>
    <secondary_id>DAIICHI-8951A-PRT016</secondary_id>
    <secondary_id>MDA-ID-99145</secondary_id>
    <secondary_id>MSKCC-99058</secondary_id>
    <secondary_id>UCHSC-00891</secondary_id>
    <nct_id>NCT00004108</nct_id>
  </id_info>
  <brief_title>DX-8951f in Treating Patients With Liver Cancer</brief_title>
  <official_title>A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have&#xD;
      liver cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Evaluate the antitumor activity of DX-8951f in terms of antitumor response,&#xD;
      response duration, and survival in patients with hepatocellular carcinoma. II. Assess the&#xD;
      quantitative and qualitative toxicities of this treatment regimen in this patient population.&#xD;
      III. Evaluate the pharmacokinetics of DX-8951 in plasma.&#xD;
&#xD;
      OUTLINE: Patients receive DX-8951f IV over 30 minutes daily for 5 days. Treatment repeats&#xD;
      every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable&#xD;
      toxicity. Patients are followed every 3 months for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study over 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1999</start_date>
  <completion_date type="Actual">April 2005</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Liver Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exatecan mesylate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed hepatocellular carcinoma with or without&#xD;
        evidence of unresectable extrahepatic metastasis Previously untreated disease OR&#xD;
        Progressive disease after first line chemotherapy Bidimensionally measurable disease by CT&#xD;
        scan, chest x-ray, or MRI of the abdomen No brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 16 and over Performance status: ECOG 0-2 Life expectancy: At&#xD;
        least 12 weeks Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count&#xD;
        at least 80,000/mm3 Hemoglobin at least 9.0 g/dL Hepatic: Bilirubin no greater than 2.0&#xD;
        mg/dL Albumin at least 2.8 g/dL SGOT/SGPT no greater than 5 times upper limit of normal&#xD;
        (ULN) PT/INR no greater than 1.5 times ULN if not on coumadin therapy Renal: Creatinine no&#xD;
        greater than 1.5 mg/dL Cardiovascular: No active congestive heart failure No uncontrolled&#xD;
        angina No myocardial infarction within the past 6 months Other: No concurrent serious&#xD;
        infection No other life threatening illness No overt psychosis or mental disability that&#xD;
        would preclude informed consent No other malignancy within the past 5 years except&#xD;
        curatively treated nonmelanomatous skin cancer or carcinoma in situ of the cervix Not&#xD;
        pregnant or nursing Negative pregnancy test Fertile patients must use effective&#xD;
        contraception 1 month prior to and during the study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic therapy Chemotherapy:&#xD;
        See Disease Characteristics At least 4 weeks since prior chemotherapy and recovered No&#xD;
        prior camptothecin analogues No other concurrent chemotherapy Endocrine therapy: Not&#xD;
        specified Radiotherapy: At least 4 weeks since prior radiotherapy and recovered No&#xD;
        concurrent radiotherapy Surgery: At least 4 weeks since prior major surgery and recovered&#xD;
        No concurrent surgery Other: No other concurrent anticancer therapy At least 4 weeks since&#xD;
        prior investigational drugs (including analgesics or antiemetics) No other investigational&#xD;
        drugs during or within 28 days after final dose of study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert L. DeJager, MD, FACP</last_name>
    <role>Study Chair</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy &amp; Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>April 15, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2004</study_first_posted>
  <last_update_submitted>May 15, 2012</last_update_submitted>
  <last_update_submitted_qc>May 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>localized resectable adult primary liver cancer</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exatecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

